This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...